Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
April 12 — The FDA's breakthrough therapy designation has led to shorter drug development times and shorter FDA review times, industry experts said April 12 during a Senate briefing.
Enacted in July 2012 as part of the Food and Drug Administration Safety and Innovation Act (Pub. L. No. 112-144), the breakthrough therapy designation expedites the development and review of drugs for serious or life-threatening conditions if the drug has demonstrated substantial improvement on at least one clinically significant endpoint over available therapies.
Jeff Allen, executive director of the Friends of Cancer Research, said pre-market development times for drugs that have received the breakthrough designation have been slightly over two years faster than drugs that haven't received the designation. Allen also said the FDA review time for these drugs is three months shorter than for drugs without the designation. The Friends of Cancer Research, a think tank and advocacy organization, sponsored the briefing.
So far, the FDA has granted 115 breakthrough therapy designations and approved 40 breakthrough products, Allen said.
Mathias Hukkelhoven, senior vice president of global regulatory, safety and biometrics for Bristol-Myers Squibb, said “we need to focus on development time more than FDA review time” because “we've seen that FDA can act very quickly.”
“The real promise of the breakthrough therapy designation is in the development time,” Hukkelhoven said. The designation allows companies to discuss with the agency how new drugs should be developed so that companies can make the right decisions, he said.
Hukkelhoven also said it's important to have collaboration between the FDA's Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health because many of the breakthrough products are biologics that have a companion diagnostic.
Janet Woodcock, director of the CDER, said the FDA has a two-page template that companies can use to apply for the breakthrough therapy designation.
Woodcock said more people need to be engaged with clinical trials and everyone should be involved, including doctors. She said recruitment for clinical trials “is a huge barrier” and getting more people engaged in trials can improve outcomes and shorten drug development times.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Janey Cohen at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)